IDEXX LABORATORIES INC /DE Deferred Revenue 2009-2026 | IDXX
Beta
What is deferred revenue?
Deferred revenue represents payments received in advance for goods or services that have not yet been delivered to customers.
What is IDEXX LABORATORIES INC /DE's current deferred revenue?
IDEXX LABORATORIES INC /DE (IDXX) annual deferred revenue for 2025 was $35.3M, a 4.33% increase from 2024. IDEXX LABORATORIES INC /DE deferred revenue for the quarter ending March 31, 2026 was $36.3M.
What was IDEXX LABORATORIES INC /DE's deferred revenue in 2024?
IDEXX LABORATORIES INC /DE annual deferred revenue for 2024 was $33.8M, a 9.13% decline from 2023.
What was IDEXX LABORATORIES INC /DE's deferred revenue in 2023?
IDEXX LABORATORIES INC /DE annual deferred revenue for 2023 was $37.2M, a 1.96% decline from 2022.
What is IDEXX LABORATORIES INC /DE's 5-year deferred revenue CAGR?
IDEXX LABORATORIES INC /DE deferred revenue grew at a compound annual growth rate (CAGR) of 3.69% from FY2020 to FY2025, going from $42.6M to $35.3M over 5 years.
Deferred Revenue History
Year-over-year comparison from 10-K annual reports
Key Statistics
Trend Direction
Stable
CAGR-3.7%
FY2020
$42.6M
→
FY2025
$35.3M
0910111213141516171819202122232425
5 years selected
Deferred Revenue History
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $35.3M | +4.3% | 10-K |
| FY2024 | $33.8M | -9.1% | 10-K |
| FY2023 | $37.2M | -2.0% | 10-K |
| FY2022 | $37.9M | -5.2% | 10-K |
| FY2021 | $40.0M | -6.0% | 10-K |
| FY2020 | $42.6M | +2.7% | 10-K |
| FY2019 | $41.5M | +0.4% | 10-K |
| FY2018 | $41.3M | +41.5% | 10-K |
| FY2017 | $29.2M | +6.6% | 10-K |
| FY2016 | $27.4M | +7.0% | 10-K |
| FY2015 | $25.6M | -19.6% | 10-K |
| FY2014 | $31.8M | +48.3% | 10-K |
| FY2013 | $21.5M | +6.3% | 10-K |
| FY2012 | $20.2M | +34.4% | 10-K |
| FY2011 | $15.0M | +7.5% | 10-K |
| FY2010 | $14.0M | +10.9% | 10-K |
| FY2009 | $12.6M | - | 10-K |
Company: IDEXX LABORATORIES INC /DETicker: IDXXSector: OtherIndustry: In Vitro & In Vivo Diagnostic SubstancesView company profile →